AbbVie Inc. (BKK:ABBV19)

Thailand · Delayed Price · Currency is THB

7.00

0.00 (0.00%)

At close: Feb 9, 2026

-0.71% (1Y)

Market Cap	12.28T +19.8%
Revenue (ttm)	1.93T +8.6%
Net Income	133.28B -1.2%
EPS	74.43 -1.3%
Shares Out	n/a
PE Ratio	92.12
Forward PE	15.28
Dividend	0.09 (1.30%)
Ex-Dividend Date	Jan 16, 2026

Volume	35,747
Average Volume	84,129
Open	6.95
Previous Close	7.00
Day's Range	6.95 - 7.10
52-Week Range	6.55 - 8.10
Beta	n/a
RSI	49.97
Earnings Date	Feb 4, 2026

About AbbVie

AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacture, commercialization, and sale of medicines and therapies worldwide. The company offers Humira, an injection for autoimmune and intestinal Behçet's diseases, generalized pustular psoriasis, and pyoderma gangrenosum; Skyrizi to treat autoimmune diseases, erythrodermic psoriasis, generalized pustular psoriasis, and palmoplantar pustulosis; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancer... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2012

Employees 55,000

Stock Exchange Stock Exchange of Thailand

Ticker Symbol ABBV19

Full Company Profile

Financial Performance

In 2025, AbbVie's revenue was $61.16 billion, an increase of 8.57% compared to the previous year's $56.33 billion. Earnings were $4.23 billion, a decrease of -0.28%.

Financial numbers in USD Financial Statements